/ /

  • linkedin
  • Increase Font
  • Sharebar

    Statins Do Double Duty Against Stroke




    A new study suggests that inpatient statin use is linked to improved outcomes after ICH, and that stopping statins during hospitalization is associated with worse outcomes. PSK9 inhibitors are a new class of injectable antihyperlipidemics that have been shown to lower LDL and may also decrease risk of cardiovascular events, including stroke. A study has suggested that evolocumab, a new PSK9 inhibitor, plus standard therapy reduces LDL by 61% and cardiovascular events by about half, compared to standard therapy alone. Another study has suggested that alirocumab, also a PSK9 inhibitor, reduces LDL by 62% and cardiovascular risk by about half, compared to placebo. • Both PSK9 agents were linked to increased rates of neurocognitive disorders 


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available